Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: A randomized placebo-controlled trial

Current Medical Research and Opinion

Volumn 31, Issue 6, 2015, Pages 1191-1200

  Zheng, Jinping ^a   De Guia, Teresita ^b   Wang Jairaj, Jie ^c   Newlands, Amy H ^c   Wang, Changzheng ^d   Crim, Courtney ^e   Zhong, Nanshan ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b PHILIPPINE HEART CENTER   (Philippines)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Xinqiao Hospital   (China)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Bronchodilator agents; Clinical respiratory medicine; Clinical trials; COPD; Respiratory function test

Indexed keywords

FLUTICASONE FUROATE PLUS VILANTEROL; GLUCOSE; HYDROCORTISONE; PLACEBO; POTASSIUM; SALBUTAMOL; ANDROSTANE DERIVATIVE; BENZYL ALCOHOL DERIVATIVE; CHLOROBENZENE; DRUG COMBINATION; FLUTICASONE FUROATE; GLUCOCORTICOID; VILANTEROL;

ACUTE HEART INFARCTION; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; ASIAN; BONE DISEASE; CARDIOVASCULAR DISEASE; CHINA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EYE DISEASE; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLUCOSE BLOOD LEVEL; HEAD INJURY; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERSENSITIVITY; HYPERTENSION; INCIDENCE; LOCAL STEROID EFFECT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OROPHARYNX PAIN; PHILIPPINES; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOUTH KOREA; TAIWAN; THORAX RADIOGRAPHY; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; ASIAN CONTINENTAL ANCESTRY GROUP; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; DRY POWDER INHALER; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AGED; ALBUTEROL; ANDROSTADIENES; ASIAN CONTINENTAL ANCESTRY GROUP; BENZYL ALCOHOLS; CHLOROBENZENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRY POWDER INHALERS; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84930372486     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1036016     Document Type: Article

References (21)

1. McKeage K. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease. Drugs 2014;74:1509-22
2. Kerwin EM, Scott-Wilson C, Sanford L, et al. A randomised trial of fluticasone furoate/vilanterol (50/25 mg; 100/25 mg) on lung function in COPD. Respir Med 2013;107:560-9
3. Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 mg) improves lung function in COPD: a randomised trial. Respir Med 2013;107:550-9
4. Dransfield MT, Bourbeau J, Jones PW, et al. A once-daily inhaled cortico-steroid, long-acting beta2-agonist combination, fluticasone furoate (FF)/vilanterol (VI), for the prevention of COPD exacerbations. Lancet Respir Med 2013;1:210-23
5. US Food and Drug Administration (FDA) 2013. Medication Guide: Breo Ellipta (fluticasone furoate and vilanterol inhalation powder). Available at: http://www.fda.gov/downloads/drugs/drugsafety/ucm352347.pdf [Last accessed 10 December 2014]
6. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (initial authorisation): Relvar Ellipta. 19th September 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion---Initial-authorisation/human/002673/WC500150090.pdf [Last accessed 10 December 2014]
7. Bjornsson TD, Wagner JA, Donahue SR, et al. A review and assessment of potential sources of ethnic differences in drug responsiveness. J Clin Pharmacol 2003;43:943-67
8. Huang SM, Temple R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther 2008;84:287-94
9. Allen A, Bal J, Cheesbrough A, et al. Pharmacokinetics and pharmacodynam-ics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects. Br J Clin Pharmacol 2014;77:808-20
10. Hankinson JL, Kawut SM, Shahar E, et al. Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest 2010;137:138-45
11. International Conference on Harmonisation Tripartite Guideline: Guidance for Good Clinical Practice E6 (R1). Available at: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6/E6-R1-Guideline.pdf [Last accessed 10 December 2014]
12. WMA Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 59th WMA General Assembly, Seoul, Korea, October 2008. Available at: http://www.wma.net/en/30publications/10policies/b3/index.html [Last accessed 10 December 2014]
13. Schünemann HJ, Griffith L, Jaeschke R, et al. A comparison of the original chronic respiratory questionnaire with a standardized version. Chest 2003; 124: 1421-9
14. McMaster University website: CRQ-SAS questionnaire can be licensed through McMaster University. Available at: http://milo.mcmaster.ca/questionnaires/questionnaires [Last accessed 10 December 2014]
15. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). Updated January 2015. Available at: http://www.goldcopd.org [Last accessed 6 March 2015]
16. Dransfield MT, Feldman G, Korenblat P, et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. Respir Med 2014; 108:1171-9
17. Agustí A, de Teresa L, De Backer W, et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J 2014;43:763-72
18. Dodd JW, Hogg L, Nolan J, et al. The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study. Thorax 2011;66:425-9
19. Jones PW, Harding G, Berry P, et al. Tests of the responsiveness of the chronic obstructive pulmonary disease (COPD) Assessment Test (CAT) following acute exacerbation and pulmonary rehabilitation. Chest 2012;142: 134-40
20. DiSantostefano RL, Li H, Hinds D, et al. Risk of pneumonia with inhaled corticosteroid/long-acting b2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis. Int J Chron Obstruct Pulmon Dis 2014;9:457-68
21. Blair HA, Deeks ED. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs 2015;75:61-74